Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.45
HSP's Cash to Debt is ranked higher than
53% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. HSP: 0.45 )
HSP' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.45

Equity to Asset 0.51
HSP's Equity to Asset is ranked higher than
59% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. HSP: 0.51 )
HSP' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.65
Current: 0.51

0.28
0.65
Interest Coverage 0.19
HSP's Interest Coverage is ranked lower than
58% of the 454 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.71 vs. HSP: 0.19 )
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 0.19

0.19
9999.99
F-Score: 7
Z-Score: 3.23
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 0.41
HSP's Operating margin (%) is ranked higher than
56% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. HSP: 0.41 )
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 0.41

0.41
16.17
Net-margin (%) -0.21
HSP's Net-margin (%) is ranked higher than
55% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. HSP: -0.21 )
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: -0.21

-0.23
11.4
ROE (%) -0.28
HSP's ROE (%) is ranked higher than
56% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. HSP: -0.28 )
HSP' s 10-Year ROE (%) Range
Min: -0.32   Max: 30.65
Current: -0.28

-0.32
30.65
ROA (%) -0.13
HSP's ROA (%) is ranked higher than
57% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. HSP: -0.13 )
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 12.87
Current: -0.13

-0.16
12.87
ROC (Joel Greenblatt) (%) 0.65
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. HSP: 0.65 )
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.65   Max: 30.37
Current: 0.65

0.65
30.37
Revenue Growth (%) 1.50
HSP's Revenue Growth (%) is ranked higher than
63% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HSP: 1.50 )
HSP' s 10-Year Revenue Growth (%) Range
Min: -0.9   Max: 12.4
Current: 1.5

-0.9
12.4
EBITDA Growth (%) -32.70
HSP's EBITDA Growth (%) is ranked higher than
50% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HSP: -32.70 )
HSP' s 10-Year EBITDA Growth (%) Range
Min: -32.7   Max: 15.4
Current: -32.7

-32.7
15.4
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HSP Guru Trades in Q3 2013

Mario Gabelli 105,870 sh (+1.73%)
Vanguard Health Care Fund 6,826,070 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Pioneer Investments 22,000 sh (unchged)
Richard Pzena Sold Out
Steven Cohen Sold Out
John Rogers 4,436,305 sh (-7.79%)
Brian Rogers 2,500,000 sh (-9.09%)
Jeff Auxier 232,930 sh (-16.36%)
Larry Robbins 3,152,089 sh (-25%)
Richard Snow 811,590 sh (-36.89%)
» More
Q4 2013

HSP Guru Trades in Q4 2013

Jim Simons 39,500 sh (New)
Steven Cohen 38,505 sh (New)
Paul Tudor Jones 14,676 sh (New)
Mario Gabelli 117,670 sh (+11.15%)
John Rogers 4,670,630 sh (+5.28%)
Vanguard Health Care Fund 6,826,070 sh (unchged)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Brian Rogers 2,500,000 sh (unchged)
Pioneer Investments Sold Out
Larry Robbins Sold Out
Richard Snow 804,722 sh (-0.85%)
Jeff Auxier 218,080 sh (-6.38%)
» More
Q1 2014

HSP Guru Trades in Q1 2014

Jim Simons 151,800 sh (+284.3%)
Mario Gabelli 153,770 sh (+30.68%)
Vanguard Health Care Fund 8,375,170 sh (+22.69%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Richard Snow Sold Out
Brian Rogers Sold Out
Jeff Auxier 205,530 sh (-5.75%)
John Rogers 4,127,850 sh (-11.62%)
Paul Tudor Jones 10,800 sh (-26.41%)
Steven Cohen 17,130 sh (-55.51%)
» More
Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.7%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-06-30 Add 32.91%0.01%$42.14 - $52.41 $ 53.7413%204370
Vanguard Health Care Fund 2014-03-31 Add 22.69%0.18%$40.89 - $45 $ 53.7426%8375170
Mario Gabelli 2014-03-31 Add 30.68%0.01%$40.89 - $45 $ 53.7425%153770
Michael Price 2013-03-31 Add 61.62%0.65%$28.96 - $35.99 $ 53.7466%400000
Vanguard Health Care Fund 2013-03-31 Add 242.15%0.62%$28.96 - $35.99 $ 53.7466%6826070
Meridian Funds 2013-03-31 New Buy0.28%$28.96 - $35.99 $ 53.7466%237400
Mario Gabelli 2013-03-31 Add 124.92%0.01%$28.96 - $35.99 $ 53.7466%107130
Mario Gabelli 2012-06-30 Add 60.16%$31.2 - $37.29 $ 53.7459%41530
Jean-Marie Eveillard 2012-03-31 Sold Out 0.09%$30.14 - $38.14 $ 53.7463%0
Ronald Muhlenkamp 2012-03-31 Sold Out 0.09%$30.14 - $38.14 $ 53.7463%0
Mario Gabelli 2012-03-31 Add 268.85%0.01%$30.14 - $38.14 $ 53.7463%25930
Ronald Muhlenkamp 2011-12-31 Reduce -91.31%1.4%$27.29 - $38.76 $ 53.7471%14650
Michael Price 2011-12-31 New Buy1.2%$27.29 - $38.76 $ 53.7471%237500
Meridian Funds 2011-12-31 Sold Out 0.23%$27.29 - $38.76 $ 53.7471%0
Vanguard Health Care Fund 2011-12-31 Add 91.32%0.16%$27.29 - $38.76 $ 53.7471%2095070
Jean-Marie Eveillard 2011-12-31 New Buy0.09%$27.29 - $38.76 $ 53.7471%650013
Mario Gabelli 2011-12-31 New Buy$27.29 - $38.76 $ 53.7471%7030
Ronald Muhlenkamp 2011-09-30 Reduce -36.56%0.93%$34.44 - $54.22 $ 53.7417%168510
Meridian Funds 2011-09-30 Add 1019.87%0.21%$34.44 - $54.22 $ 53.7417%169100
George Soros 2011-09-30 Sold Out 0.0798%$34.44 - $54.22 $ 53.7417%0
George Soros 2011-06-30 Reduce -85.73%0.52%$53.74 - $58.13 $ 53.74-3%100200
Meridian Funds 2011-06-30 New Buy0.03%$53.74 - $58.13 $ 53.74-3%15100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira Inc

John Rogers Comments on Hospira Inc. - Jul 25, 2013

Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.

From John RogersAriel Fund Second Quarter 2013 Commentary.


Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 52.10
HSP's P/E(ttm) is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. HSP: 52.10 )
HSP' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 133.97
Current: 52.1

8.48
133.97
P/B 2.79
HSP's P/B is ranked higher than
68% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. HSP: 2.79 )
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 2.79

1.52
5.83
P/S 2.11
HSP's P/S is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. HSP: 2.11 )
HSP' s 10-Year P/S Range
Min: 0.99   Max: 2.89
Current: 2.11

0.99
2.89
PFCF 199.04
HSP's PFCF is ranked higher than
72% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. HSP: 199.04 )
HSP' s 10-Year PFCF Range
Min: 8.32   Max: 203.78
Current: 199.04

8.32
203.78
EV-to-EBIT 35.59
HSP's EV-to-EBIT is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. HSP: 35.59 )
HSP' s 10-Year EV-to-EBIT Range
Min: 10   Max: 508.2
Current: 35.59

10
508.2
Shiller P/E 43.99
HSP's Shiller P/E is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. HSP: 43.99 )
HSP' s 10-Year Shiller P/E Range
Min: 12.62   Max: 45.1
Current: 43.99

12.62
45.1
Current Ratio 2.57
HSP's Current Ratio is ranked higher than
71% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. HSP: 2.57 )
HSP' s 10-Year Current Ratio Range
Min: 1.61   Max: 3.03
Current: 2.57

1.61
3.03
Quick Ratio 1.59
HSP's Quick Ratio is ranked higher than
66% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. HSP: 1.59 )
HSP' s 10-Year Quick Ratio Range
Min: 1   Max: 2.04
Current: 1.59

1
2.04

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.44
HSP's Price/Tangible Book is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. HSP: 4.44 )
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 76.38
Current: 4.44

3.04
76.38
Price/DCF (Projected) 1.88
HSP's Price/DCF (Projected) is ranked higher than
87% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. HSP: 1.88 )
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 1.78
Current: 1.88

0.91
1.78
Price/Median PS Value 1.10
HSP's Price/Median PS Value is ranked higher than
76% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. HSP: 1.10 )
HSP' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.38
Current: 1.1

0.62
1.38
Price/Graham Number 3.20
HSP's Price/Graham Number is ranked higher than
74% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.75 vs. HSP: 3.20 )
HSP' s 10-Year Price/Graham Number Range
Min: 1.85   Max: 9.99
Current: 3.2

1.85
9.99
Earnings Yield (Greenblatt) 2.80
HSP's Earnings Yield (Greenblatt) is ranked higher than
60% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. HSP: 2.80 )
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 2.8

0.2
10
Forward Rate of Return (Yacktman) 2.25
HSP's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. HSP: 2.25 )
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.6   Max: 18.8
Current: 2.25

2.6
18.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany
Hospira, Inc. was incorporated in Delaware on September 16, 2003, as a wholly owned subsidiary of Abbott Laboratories. On April 30, 2004, it began operating as an independent company. The Company is a global provider of injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. The Company's specialty injectable pharmaceutical products category mainly consists of generic injectable pharmaceuticals. These products provide customers with a lower-cost alternative to branded products, when the patent protection has expired, when patents have been declared invalid, or when the products do not infringe the patents of others. These drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. The Company's other pharmaceuticals mainly consist of large volume I.V. solutions, nutritionals and contract manufacturing services. The Company offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. It also offers infusion therapy solutions in its VisIV(TM) next-generation non-PVC, non-DEHP I.V. container, an I.V. bag with advanced safety and environmentally friendly features. Its contract manufacturing services are offered through its One2One(SM) services group, which provides formulation development, filling and finishing of injectable and oral drugs worldwide. The Company's medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to the company's pumps. These sets are used to deliver I.V. fluids and medications. Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers. The Company's main customers in the Americas segment include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its main customers in the EMEA and APAC segments are hospitals and wholesalers that serve through its own sales force and its distributors. In the U.S., the
» More Articles for HSP

Headlines

Articles On GuruFocus.com
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
Five Companies Cut - Pzena Investment Management Update Nov 12 2013 
John Rogers Comments on Hospira Inc. Jul 25 2013 
Rowe Price Equity Income Fund Buys Apple, Carnival, Joy Global, Sells Thermo Fisher, Energizer, SLM Jul 19 2013 
John Rogers Ariel Fund Second Quarterly Commentary Jul 18 2013 
Brian Rogers' Top 3 Increases and Decreases of Q2 Jul 17 2013 
comment on HSP May 22 2013 
Brian Rogers of T Rowe Price Buys 4 New Stocks, Including Apple in Q1 Apr 17 2013 


More From Other Websites
[$$] Judge's Order Delays FDA Approval for Generic Form of Hospira Drug Aug 21 2014
Tata Motors, Tupperware Brands, Hospira, Mylan and Mallinckrodt highlighted as Zacks Bull and Bear... Aug 21 2014
HOSPIRA INC Files SEC form 8-K, Other Events Aug 20 2014
Hospira Sues FDA on Generic Precedex Approval, Shares Down Aug 20 2014
U.S. judge blocks FDA rule allowing generic versions of Hospira drug Aug 20 2014
[$$] Hospira Sues FDA Over Generic Precedex Aug 19 2014
Apple sets record close; Loco slides on analyst caution Aug 19 2014
Why Hospira (HSP) Stock Is Lower Today Aug 19 2014
Hospira sues FDA over generic approvals for its sedative Precedex Aug 19 2014
HOSPIRA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events Aug 19 2014
Hospira to Present at the Morgan Stanley Global Healthcare Conference Aug 15 2014
Top U.S. lawmaker urges Hospira not to flee tax system Aug 14 2014
Senior U.S. lawmaker urges Hospira not to flee U.S. tax system Aug 14 2014
Will Hospira (HSP) Crush Estimates at Its Next Earnings Report? Aug 07 2014
HOSPIRA INC Financials Aug 06 2014
Premier, Inc. Continues Growth Trajectory With Acquisition of Hospira's TheraDoc, Expanding Industry... Aug 05 2014
Hospira Inc. (HSP) Jumps: Stock Adds 8.3% in Session Jul 31 2014
Hospira Beats on Earnings and Sales in Q2, Boosts Guidance Jul 30 2014
[$$] Hospira Profit More Than Doubles Jul 30 2014
Hospira beats profit estimates, raises 2014 outlook Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK